RT Journal Article
SR Electronic
T1 How to better communicate exponential growth of infectious diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.12.20129114
DO 10.1101/2020.06.12.20129114
A1 Schonger, Martin
A1 Sele, Daniela
YR 2020
UL http://medrxiv.org/content/early/2020/06/14/2020.06.12.20129114.abstract
AB Sustained non-pharmaceutical interventions (NPIs) can contain the spread of infectious disease when vaccines or treatments are not available1-3. The benefit of such behavioural adaptations can be modelled as the deceleration of the exponential growth of cases. Humans underestimate exponential growth, as has been documented in biological4, environmental5-6 and financial contexts7-13. Hence, they might also underestimate the benefit of reducing the exponential growth rate. Different ways of communicating the same scenario, i.e. frames, have been found to have a large impact on people’s evaluations and choices in the contexts of social behaviour14,15, risk taking16-19 and health care20-23. Here we show that framing matters for people’s assessment of the benefits of measures to mitigate the spread of infectious disease. In two commonly used frames, most subjects in our experiment drastically underestimate the number of cases mitigation measures avoid. Framing growth in terms of doubling times, rather than growth rates, improves understanding. In a non-standard framing, which focuses on time gained rather than cases avoided, the median subject assesses the benefit of mitigation measures correctly. These findings suggest changes that public health authorities can adopt to communicate the exponential spread of infectious disease more effectively. Beyond public health, the findings have applications to, for example, the regulation of the sale of financial products, retirement savings, education and the public understanding of exponential processes in the environment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementETH Zurich and Swiss National Science Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ETH Zurich Ethics Commmission. Number: 2020-N-36All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available from the authors. We are uploading the associated data file (Excel) to medrxiv.org.